Cigna raised its 2026 profit forecast to at least $30.45 per share on the strength of second-quarter results that beat expectations, the health insurance company announced on July 30, driven by strong performance in its specialty drug and pharmacy services division.
The company reported Q2 adjusted income from operations of $7.78 per share, surpassing analyst expectations of $7.60, according to FactSet. Total revenues for the quarter increased 7% to $71.7 billion compared with the year-ago period, reflecting growth across both the Evernorth Health Services and Cigna Healthcare segments.
The updated guidance represents a $0.10 increase from Cigna’s prior outlook of at least $30.35 per share for the full year. The company noted that the revision reflects solid operational performance and the effectiveness of its strategy, which centers on using technology, data, and AI to deliver more personalized healthcare experiences and lower costs.
Evernorth’s Specialty and Care Services unit, which handles specialty drugs for complex and rare diseases, posted particularly strong results. Pre-tax adjusted earnings in that division grew 22% year-over-year to $1.1 billion, driven by strong specialty volume growth and higher adoption of generic and biosimilar drugs that benefit both clients and patients through lower costs. This growth offset weaker performance in Cigna’s Pharmacy Benefit Services division, where adjusted income fell 27% due to large client contract renewals and customer-focused initiatives.
Cigna Healthcare, the company’s medical insurance segment, also contributed to the upbeat results. Adjusted income from operations in that division rose 17% to $1.3 billion, primarily reflecting improved margins within its U.S. Employer business. The segment’s adjusted revenues increased 9% to $11.7 billion, driven by premium rate increases to cover expected medical cost increases.
The health insurance industry has faced significant headwinds from rising medical costs in 2026, with employers projecting median healthcare cost trend increases of 9% for the year. However, several major insurers have reported better-than-expected Q2 results. UnitedHealth Group, the nation’s largest private insurer, raised its 2026 earnings guidance in July after beating Q2 expectations, citing controlled medical costs. Elevance Health and Humana also beat earnings estimates in the quarter as medical costs moderated in certain health plans.
Cigna’s net income for Q2 reached $1.7 billion, or $6.29 per share, compared with $1.5 billion, or $5.71 per share, in the same quarter last year. The company also announced it repurchased 0.9 million shares for approximately $250 million through late July.
Sources
- The Cigna Group Newsroom — Q2 2026 earnings announcement with full financial results, segment performance, and 2026 outlook guidance
- FactSet — Q2 2026 earnings estimates and analyst consensus figures
- Reuters — Cigna’s specialty drug strength and Evernorth revenue growth details
- MarketBeat — Specialty and Care Services earnings growth and segment performance
- Quartz — Full-year guidance increase and prior outlook comparison
- Business Group on Health — 2026 employer healthcare cost trend projections
